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Available online 02 November 2016Purpose:MRI has become an essential tool for prion disease diagnosis. However there exist only a few serial MRI
studies of prion patients, and these mostly used whole brain summary measures or region of interest based ap-
proaches. We present here the ﬁrst longitudinal voxel-based morphometry (VBM) study in prion disease. The
aim of this study was to systematically characterise progressive atrophy in patients with prion disease and iden-
tify whether atrophy in speciﬁc brain structures correlates with clinical assessment.
Methods: Twenty-four prion disease patients with early stage disease (3 sporadic, 2 iatrogenic, 1 variant and 18
inherited CJD) and 25 controls were examined at 3Twith a T1-weighted 3DMPRAGE sequence atmultiple time-
points (2–6 examinations per subject, interval range 0.1–3.2 years). Longitudinal VBMprovided intra-subject and
inter-subject image alignment, allowing voxel-wise comparison of progressive structural change. Clinical disease
progression was assessed using theMRC Prion Disease Rating Scale. Firstly, in patients, we determined the brain
regionswhere grey andwhitematter volume change betweenbaseline andﬁnal examination correlatedwith the
corresponding change in MRC Scale score. Secondly, in the 21/24 patients with interscan interval longer than
3 months, we identiﬁed regions where annualised rates of regional volume change in patients were different
from rates in age-matched controls. Given the heterogeneity of the cohort, the regions identiﬁed reﬂect the com-
mon features of the different prion sub-types studied.
Results: In the patients there were multiple regions where volume loss signiﬁcantly correlated with decreased
MRC scale, partially overlapping with anatomical regions where yearly rates of volume loss were signiﬁcantly
greater than controls. The key anatomical areas involved included: the basal ganglia and thalamus, pons andme-
dulla, the hippocampal formation and the superior parietal lobules. There were no areas demonstrating volume
loss signiﬁcantly higher in controls than patients or negative correlation between volume and MRC Scale score.
Conclusions: Using 3T MRI and longitudinal VBM we have identiﬁed key anatomical regions of progressive vol-
ume loss which correlate with an established clinical disease severity index and are relevant to clinical deterio-
ration. Localisation of the regions of progressive brain atrophy correlatingmost stronglywith clinical declinemay
help to provide more targeted imaging endpoints for future clinical trials.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
Prion disease
Structural MRI
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Humanprion diseases are rare progressive neurodegenerative disor-
ders caused by the propagation of an abnormally folded form of prion
protein in the brain (Prusiner, 1982; Collinge, 2000). Three etiological
groups include inherited forms caused by mutation of the gene
encoding prion protein (inherited), acquired forms from prion contam-
ination of food, medical products or instruments (variant or iatrogenic),
and sporadic forms of unknown etiology (Collinge, 2001). Prion dis-
eases are heterogeneous, may mimic other neurodegenerative diseasesthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Whilst therapeutic agents that have shown potential to slow disease
progression are in preclinical development, there is currently no effec-
tive clinical treatment and prion diseases are uniformly fatal.
MRI has become increasingly important for the diagnosis of speciﬁc
forms of prion disease (Wang et al., 2013). On conventional MRI, classi-
cal radiological signs of sporadic CJD are high signal in the striatum on
T2-weighted, FLAIR and diffusion-weighted (DW) images, as well as
localised cortical or thalamic high signal in FLAIR and DW images
(Vitali et al., 2011; Tschampa et al., 2007; Eisenmenger et al., 2016). Ab-
normally high signal in the pulvinar nucleus of the thalamus compared
to anterior putamen bilaterally is a highly speciﬁc characteristic of var-
iant CJD (Zeidler et al., 2000).
Quantitative MRI is extremely useful in providing objective data, in-
dependent of subjective signal intensity assessments, A number of pub-
lications have pioneered quantitative brain MRI in prion diseases,
focused in particular upon DW imaging and tissue-volume assessment
(Lin et al., 2006; Lee et al., 2009; Cohen et al., 2009 (cerebellar atrophy);
Lee et al., 2010; Hyare et al., 2010a, 2010b; Alner et al., 2012 (cortical
thickness); Lee et al., 2012; De Vita et al., 2013 (someVBMatrophyﬁnd-
ings); Wang et al., 2013; Caverzasi et al., 2014a, 2014b) as well as
magnetisation transfer ratio (Siddique et al., 2010) and metabolite con-
centrations (Galanaud et al., 2010).
Many of these studies have relied upon manually traced regions of
interest (ROIs) for numerical analysis. This approach has high anatomi-
cal speciﬁcity yielding high statistical sensitivity, but is labour intensive
and operator dependent, susceptible to intra- and inter-observer varia-
tions, and moreover probes only a priori selected brain regions. Voxel
based morphometry (VBM) (Wright et al., 1995; Ashburner and
Friston, 2000) allows voxel-by-voxel MRI group data comparison
whereby local, tissue-type speciﬁc structural differences can be detect-
ed using mass-univariate statistics similar to those employed in fMRI
studies. One of the key beneﬁts is the ability to assess all brain regions
simultaneously without a priori assumptions.
Though atrophy is typically not an early ﬁnding on conventionalMRI
in prion diseases, VBM of cross-sectional MRI has been able to reveal
sporadic CJD cerebellar atrophy (Cohen et al., 2009) and, with a more
sophisticated normalization procedure (DARTEL (Ashburner, 2007)),
patterns of atrophy in the 6-OPRI variant of inherited prion disease
(De Vita et al., 2013). Voxel based analysis of DW imaging or diffusion
tensor imaging (DTI), using a similar approach to VBM have also been
reported (Lee et al., 2009; De Vita et al., 2013). Tract based spatial statis-
tics (Smith et al., 2006), developed to resolve some of the issues associ-
atedwithwhitematter tract co-registration has also been used to assess
WM disruption in prion disease using DTI (Lee et al., 2012).
An alternative approach to VBM for determining regional volume
loss, applied in a prion disease patient cohort by (Caverzasi et al.,
2014a, 2014b) automatically parcellates a large number, i.e. 40 per
hemisphere, of anatomical regions of interest (ROI) using matching al-
gorithms to transfer cortical and subcortical ROI labels from a manually
labelled template to individual structural scans, and is exempliﬁed in
the FreeSurfer package (Fischl et al., 2004).
If quantitative MRI is to be useful in assessing the efﬁcacy of new
prion disease treatments, it is important to understand how the pre-
sumed progression of brain microstructural changes (formation of
prion protein aggregates, spongiosis, astrocytic gliosis, nerve cell loss)
inﬂuences MRI-derived metrics. Establishing the relationship of these
metrics with clinical disease severity over time is an important step in
the development of MRI biomarkers for therapeutic trials.
To date only a few publications have investigated serial brain MRI in
prion disease patients. Many of these are single case reports (Fox et al.,
1997; Kono et al., 2011;Matoba et al., 2001; Tribl et al., 2002), or studies
with fewer than ten subjects (Murata et al., 2002) (n=8), (Caverzasi et
al., 2014a, 2014b; Eisenmenger et al., 2016) (n=7), (Ukisu et al., 2005)
(n = 9), whilst Siddique et al. (2010)) studied 18 inherited prion
patients.While earlier MRI studies in prion disease have been performed
mainly at 1.5T, contemporary 3T scanners with multi-element receive
coils offer signiﬁcant sensitivity beneﬁts. As part of the UK National
Prion Monitoring Cohort study (Thompson et al., 2013), in this work
we examined serially with 3T high-resolution brain structural MRI a co-
hort of patients with various forms of prion disease, the majority being
diagnosed with inherited prion disease. We aimed to use longitudinal
VBM to objectively characterise progressive structural brain changes
without a priori assumptions. The longitudinal VBM approach maxi-
mizes sensitivity to individual serial changes (Chételat et al., 2005)
and has not been used previously to study prion diseases. We hypothe-
sized that measurable macroscopic changes in brain tissue volumes re-
ﬂect the development of microscopic brain pathology. Measuring local
brain-tissue volume changes between ﬁrst and last scan in patients,
we identiﬁed regions in which longitudinal tissue volume loss correlat-
ed with the concomitant change in the recently proposed MRC Prion
Disease Rating Scale (MRC Scale), a functionally-orientated outcome
measure for prion disease patients (Thompson et al., 2013). We also
computed the yearly rate of tissue volume change in order to map the
regional distribution of longitudinal brain atrophy for prion patients in
comparison with age-matched healthy individuals. By including a clini-
cally and etiologically heterogenous group of patients in our cohort we
highlight key anatomical regions showing atrophy on average across
the different forms of prion disease studied.
2. Methods
2.1. Subjects
This studywas approved by the Scotland A Research Ethics Commit-
tee and all participating subjects or their carers provided informed con-
sent. From a total cohort of 95 patients undergoing research MRI
between September 2009 and March 2013, we included data from all
the subjects in which 2 or more artefact-free structural scans were ob-
tained (n = 24). Data from 25 healthy control subjects matched for
age to the patients and scanned over the same periodwas also included.
A total of 126 scanswere analysed. Healthy controls were scanned at 12
monthly intervals whilst symptomatic patients were scanned at 3–6
monthly intervals and rapidly progressive patients at 6–8 week inter-
vals where possible.
All patients had a neurologist-conﬁrmed diagnosis of probable or
deﬁnite prion disease. Three had the sporadic form (sporadic CJD), 3
the acquired form (1 variant, 2 iatrogenic) and 18 the inherited form
(6 P102L, 3 5-OPRI, 3 A117V, 2 6-OPRI, 2 Y163X, one each of D178N
and E200K mutations of the prion protein gene). Data from all of the
24 patients were included in the analysis correlating changes in local
brain volume andMRC Scale change. Three patients (1 sporadic, 1 iatro-
genic, 1 variant) were excluded from the analysis of yearly rates of GM
and WM volume change because of an insufﬁcient time interval (b-
3 months) between ﬁrst and last examination (further details below).
2.2. MRI
MRI was performed at 3T (TIM Trio; Siemens, Erlangen, Germany)
with the conventional body coil for transmission and a 32-channel
head-only receive coil. Structural imaging used a 3D T1-weighted
MPRAGE sequence with repetition time 2.2 s, echo time 2.9 ms, inver-
sion time 900 ms, echo spacing 6.7 ms, ﬂip angle 10°, Field of View
282 × 282 × 228 mm3, matrix 256 × 256 × 208 with 1.1 mm sagittal
partitions, acquisition time 9′23″.
2.3. Clinical assessment
All participants underwent detailed systematic neurological and
neuropsychological examination and scoring on the MRC Scale
(Thompson et al., 2013). The MRC Scale examination assesses domains
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nence, weighted according to their relative importance in the disease,
and gives a global indication of disease severity. This 20-point function-
ally-oriented scale is advantageous over single scales for its simplicity of
administration and ability to capture the rapid changes that can charac-
terise the disease. Its performance in a large cohort of sporadic CJD pa-
tients demonstrated conformity with the Rasch model, indicating
linearity, that is, a decline from 20 to 19 is equivalent in magnitude to
a decline from 1 to 0, permitting the valid correlation of group MRC
Scale with imaging parameters. This assessment was repeated for each
patient on the same day as each of their MRI scans.
2.4. Longitudinal VBM preprocessing
Longitudinal VBMwas performed usingMATLABwith in-house pro-
cessing scripts and SPM81 tools similarly to methods described in
(Rohrer et al., 2013). In brief, the following steps were performed:
(a) Images acquired at several time-points from each subject were
ﬁrst segmented using ‘uniﬁed segmentation’ (Ashburner and
Friston, 2005) (‘New Segment’ tool), and images were bias
corrected and intensity normalised to have consistent white
matter (WM) mean intensity.
(b) Images were rigidly aligned then non-rigidly warped to their (it-
eratively evolving)within-subject average using the high dimen-
sional warping algorithm (HDW) (Ashburner and Friston, 2000).
This spatial processing methodology removes the bias that
would be present if simply registering to the 1st or last scan
(Reuter et al., 2012).
(c) Each of thewithin-subject averages was then re-segmented as in
(a), and individual pseudo-time-points were obtained by
multiplying the average tissue segment by the Jacobian of the
deformation needed to warp the original dataset to the within-
subject average, similarly to (Chételat et al., 2005). Thismodulation
accounts for warp-associated volume changes (Mechelli et al.,
2005). For each subject, the total intracranial volume (TIV) was
calculated from each within-subject average by adding up GM,
WM and CSF tissue segments volumes.
(d) DARTEL (Ashburner, 2007) was used for the 49 individual subject
averages to generate cohort-speciﬁc GM and WM templates at
(1.5 mm)(Ashburner and Friston, 2005) resolution.
(e) Individual subject GM and WM segments from (d) were warped
to these template voxel intensities again modulated to account
for normalization-associated volume changes (Mechelli et al.,
2005). Smoothing was then performed (6 mm full width half
maximum Gaussian kernel).
(f) The ‘optimal threshold’method (Ridgway et al., 2009)was applied
separately to the average GM and WM segments to generate
inclusion masks for statistical analysis.
2.5. Statistical analysis
Differences between age at 1st scan and TIV between groups were
assessed with a t-test.
2.5.1. Assessment of regional correlations between brain volume loss and
MRC Scale
TheMRCScale captures a number of clinical features of prion disease
that appear to be most valuable in assessing disease progression
(Thompson et al., 2013). To determine the validity of longitudinal
VBM as a marker of clinically meaningful disease progression, we
aimed to identify neuroanatomically speciﬁc regions in which volume
loss correlatedwith change in individual MRC Scale over the same peri-
od in this patient group.1 http://www.ﬁl.ion.ucl.ac.uk/spm/software/spm8/.The cohort we studied was clinically and etiologically heterogenous
and comprised patients demonstrating both slow and rapid deteriora-
tion of functional and neurological skills, reﬂected in markedly variable
rates of decline in MRC Scale with time, with trajectories that are not
necessarily linear over the whole monitoring period, especially in the
initial and ﬁnal stages (Thompson et al., 2013). As a consequence, it
was not appropriate in group analyses to assess imaging changes over
a common time interval for all patients, and therefore we correlated
group regional brain-volume change with MRC Scale decline, each var-
iable computed as the difference between baseline and ﬁnal examina-
tion values.
Subjects for whom themaximum inter-scan interval was very small
have problematically imprecise rates of change. Thus, for the purpose of
establishing associations between longitudinal tissue volume and MRC
Scale decline, absolute changes were correlated rather than temporal
rates of change. In contrast, working directly with absolute changes en-
sures data for all patients contribute similarly, whether they are slow-
progressing or fast-progressing.
Therefore, for all 24 patients, MRC Scale change (ΔMRC) was calcu-
lated as the difference between scores obtained at the times of the
ﬁrst and last MRI examinations. Correspondingly GM and WM volume
differences (ΔGM and ΔWM) between ﬁrst and last MRI scans were
computed. Voxel-wise correlation was performed between ΔGM (and
ΔWM separately) and ΔMRC in SPM, using the intermediate age of
each patient between ﬁrst and last scan (ageLast + ageFirst)/2 as a covar-
iate of no interest.
To provide upper and lower bound effect size estimates, we report
the average of the slope for the regression of MRC and volume change
computed over (a) the signiﬁcant voxels, whichwill yield an inﬂated es-
timate due to circularity (Kriegeskorte et al., 2010), and (b) all in-mask
voxels, whichwill yield an underestimate due to dilution fromunaffect-
ed voxels.
For some of the regions that showed signiﬁcant results, wemanually
drew ROIs on corresponding anatomical structures on the T1-weighted
images and plotted for each of the 24 patients, the variation in GM
(ΔGM) vs the variation in MRC Scale (ΔMRC) between ﬁrst and last
scan. We also performed a linear regression of ΔGM vs ΔMRC.
2.5.2. Assessment of regional yearly GM and WM rates of change
We also assessed the patterns of longitudinal brain atrophy in prion
patients compared with controls. Voxel-wise yearly rates of GM and
WM volume change, presumed to represent atrophy rates when nega-
tive and local growth/swelling rates if positive,were calculated by linear
regression using all available individual time-points for each subject.
For this analysis, subjects with maximum inter-scan intervals of b-
3monthswere excluded, to avoid disproportionate propagation ofmea-
surement noise caused by small changes in the short interval, as
discussed above. As a consequence data from 1 sporadic, 1 iatrogenic
and 1 variant patient were not included in the analysis.
Statistically signiﬁcant group differences in yearly voxel-wise vol-
ume change between controls and the remaining patients (n = 21),
were evaluated separately for GM and WM, with intermediate age be-
tween ﬁrst and last scan as a covariate of no interest. Effect size maps
were also computed showing the difference in yearly volume change
between patients and controls.
Here, for illustration of effect size we reported the average effect
over all signiﬁcant voxels (upper bound) as well as over a mask deﬁned
by the voxels where the average slope across controls and patients is
signiﬁcant (lower bound). Note that the difference is essentially orthog-
onal to the average, due to the almost equal group sizes, so there is no
concern over circularity with this effect size estimate.
2.5.3. Statistical thresholds and display
SPM-t maps were computed, corrected for multiple comparisons
using false discovery rate (FDR) with p b 0.05. Although analysis of
WM and GM fractional tissue volume differences were performed
Fig. 1. MRC Scale change over time for each of the 24 patients. Different etiologies and
genetic mutations are shown in different colours. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 2
Individual data for patients: prion disease etiology, intermediate age between theﬁrst and
last scan (Age), disease duration (DD), total number of scans (Nscans), time interval be-
tween ﬁrst and last scan (tlast − tﬁrst), change in MRC Scale between these timepoints
(ΔMRC). $: years. #: ﬁrst scan before onset. &: ﬁrst 2 scans before onset.
ID Prion disease etiology Age$ DD$ Nscans tlast − tﬁrst$ ΔMRC
P06 5-OPRI 48.99 2.29 6 3.26 4
P12 5-OPRI 52.22 5.71 3 1.03 4
P13 5-OPRI 48.67 6.71 5 2.15 1
P08 6-OPRI 42.51 3.63 3 1.23 1
P05 6-OPRI 42.25 5.85 3 1.69 1
P15 A117V 38.50 1.66 2 0.40 1
P16 A117V 51.21 2.18 2 0.42 3
P03 A117V 38.57 1.21 3 1.13 9
P09 D178N 52.67 0.63 2 0.35 5
P20 E200K 46.19 -0.50# 2 0.69 2
P04 P102L 50.73 2.52 2 0.86 0
P07 P102L 62.98 1.57 5 2.36 8
P17 P102L 56.48 -0.77& 4 2.76 2
P19 P102L 55.23 1.38 2 0.56 7
P11 P102L 61.07 0.87 3 1.94 6
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SPMs were afﬁne transformed to the standard MNI anatomical
space, using parameters obtained by afﬁne-registering theDARTEL tem-
plate to the MNI space tissue prior-probability maps. Results are
displayed overlaid on the average of all warped and smoothed T1 vol-
umes, transformed to MNI space. All are presented using the radiologi-
cal convention (patient's right hemisphere on left of the ﬁgures).
3. Results
Summary statistics for the group age atﬁrst scan and TIV are given in
Table 1, neither was signiﬁcantly different between controls and pa-
tients groups (p=0.7 for both). There was also no difference in gender
between groups (p= 0.5).
3.1. Timing of MRI examinations
Nineteen out of the 49 subjects hadmore than two scans: 6 controls
(with 3 scans), 13 patients (8 with 3 scans, 1 with 4, 2 with 5, 2 with 6
scans). Supplementary Fig. S1 displays individual subject examination
timepoints (in years from the initialMRI scan)) for patients (a) and con-
trols (b).
All subjects underwent at least 2 examinations, the second per-
formed at 1.2 ± 0.49 (mean ± SD) years post-baseline for controls
(range 0.44–2.93 years), and 0.55 ± 0.27 years (range 0.12–
1.02 years), for patients. For those subject undergoing 3 examinations,
the third timepoint was at 1.7 ± 0.41 years for controls (n = 6), and
1.03 ± 0.64 years (n= 16) for patients. Including all subjects the inter-
val between ﬁrst and last scan was 1.38 ± 0.53 years for controls and
1.19 ± 0.91 years for patients (no difference, p= 0.4).
3.2. MRC scale
All controls had anMRC Scale of 20. The patients entered the trial at
an early disease stage: themean (sd)MRC Scale at ﬁrst scan for patients
was 18.1 (1.6) with median (range) 18 (14–20). As expected, for pa-
tients the MRC Scale typically decreased monotonically, with varying
rates of decline. The MRC Scale on the last scan was 13.9 (4.0), with a
median (range) was 15 (4–19). The MRC Scale trajectories for each of
the 24 patients are shown in Fig. 1 with different etiologies or inherited
mutations shown in different colours. It is apparent that there is a range
of rates of clinical progressions, and even patientswith the same genetic
mutation or etiology can progress at very different rates.
Table 2 summarises for each patient, the prion disease form (or spe-
ciﬁc genetic mutation for the inherited cases), age, the disease duration
at ﬁrst scan (date from onset of ﬁrst symptoms) the total number of
scans, the time interval between ﬁrst and last scan and ΔMRC.
3.3. Imaging results
3.3.1. Correlation of brain volume changes with MRC Scale change in
patients
There was a signiﬁcant correlation between tissue volume change
between the ﬁrst and last examination, and change in MRC Scale over
the same period, across several brain areas, with decreases in MRC
Scale accompanied by decreases in local GM and/or, WM tissue vol-
umes. Considering the whole analysis mask themean fractional volumeTable 1
Group ages and total intracranial volume. #: median (range).
Controls (n = 25) Patients (n = 24)
Gender 13 males 13 males
Age at 1st examination# (years) 46.5 (23.8–69.4) 49.0 (25.0–76.7)
Total intracranial volume# (litres) 1.50 (1.29–1.83) 1.52 (1.21–1.85)decrease in GM (WM) was 0.00181 (0.00227) per each point decrease
in MRC Scale. No areas demonstrated a signiﬁcant negative correlation.
Fig. 2A displays the areas of signiﬁcant positive correlation (at FDR
p b 0.05) between ΔGM and ΔMRC (red-yellow) as well as between
ΔWMandΔMRC (blue-cyan). In summary, therewere clusters showing
signiﬁcant correlation bilaterally in the insular cortex, head of caudate
and putamen, thalamus, hippocampus and cerebellum, superior parietal
lobule, genu and splenium of the corpus callosum, midbrain, medulla
and pons. There were right sided GM clusters in the amygdala, middle
temporal gyrus, inferior frontal gyrus and parahippocampaly gyrus.
On the left, GM clusters in the precuneus and superior occipital gyrus.
Also WM clusters in the vertical ﬁbers of the arcuate fasciculus and
thalamo-cortical ﬁbers of the cortico-spinal tract (full results for all sig-
niﬁcant clusters are reported in Supplementary Files 1 and 2). In termsP14 P102L 42.85 0.04 6 2.49 9
P18 Y163X 43.72 9.98 3 1.59 1
P10 Y163X 54.19 15.23 2 1.02 2
P01 Iatrogenic CJD 47.08 0.43 3 0.36 10
P02 Iatrogenic CJD 44.15 0.75 2 0.12 6
P21 Sporadic CJD 59.36 0.62 2 0.12 6
P22 Sporadic CJD 59.50 2.21 3 1.59 10
P23 Sporadic CJD 77.00 0.96 2 0.33 1
P24 Variant CJD 25.12 0.22 2 0.23 1
Fig. 2. (A) SPM-t maps showing signiﬁcant positive correlation (FDR p b 0.05) between reduction in tissue volume, ΔGM (red-yellow) or ΔWM (blue-cyan), and ΔMRC Scale when
comparing ﬁrst and last scan. For GM there were 10,149 suprathreshold (t N 3.31) voxels over 308,090 tested; the median/mean t (sd) over these voxels was 3.75/3.91(0.55); for WM
there were 15,636 voxels (with t N 2.88) over 176,008; the median/mean t over these was 3.46/3.75(0.85). (B). SPM-t maps showing GM (pink) and WM (green) areas where atrophy
in patients was greater than in controls (FDR p b 0.05). For GM there were 35,121 supra-threshold (t N 2.64) voxels over 308,090 tested; the median/mean t (sd) over these was 3.02/
3.12(0.40); for WM: 8740 supra-threshold (t N 2.96) over 176,008, with median/mean t (sd) 3.40/3.52(0.46). For each section, MNI coordinates are shown. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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last scans were on average 0.018 (0.011) (mean (sd)) and ΔWM 0.029
(0.015); the average slope of ΔGM decrease per one point decrease in
MRC Scale was 0.0074(0.0025) for GM and 0.0086(0.0037) for ΔWM.
3.3.2. Yearly rates of GM and WM volume change
The voxel-wise linear rate of tissue volume change for patients was
lower (more negative) than for controls in 86.7% of GM tissue voxels
and in 71.6% of WM voxels.
These differences were signiﬁcant in numerous anatomical regions
(Fig. 2B) (details of signiﬁcant clusters MNI coordinates in Supplemen-
tary Files 3 and 4). All of these areas were in regions where the patients
groupdisplayed on average negative rates of change, thus theseﬁndings
indicate signiﬁcant yearly atrophy in patientswith respect to controls as
conﬁrmed by visual inspection of the effect size maps (for GM Supple-
mentary Fig. S2, for WM Supplementary Fig. S3).
Areas of signiﬁcantly increased atrophy rates in patients that also o-
verlapped with areas showing signiﬁcant correlation between volume
loss and MRC Scale decrease included: insular cortex, hippocampus,
head of caudate, thalamus, putamen, the IFG, part of the pons, the
genu of the corpus callosum and parts of the corticospinal tract. Other
areas with signiﬁcant atrophy rate differences compared with controlsincluded the body of the corpus callosum, large areas of the cingulate
gyrus, parts of the superior and middle temporal gyri, some areas of
the superior and middle frontal gyri, and the fusiform gyrus. Supple-
mentary Fig. S4 shows ΔGM vs ΔMRC in the putamen (A) and head of
caudate (B) in the right hemisphere for each individual patient together
with the least square regression line when combining all patients. Pa-
tients with different etiologies or inherited mutations are shown in dif-
ferent colours as in Fig. 1.
Over the voxels where the average slope of control and patients
was signiﬁcant (FDR p b 0.05), the yearly rate of volume fraction
change was−0.027 (0.011) for patients and 0.0028 (0.0034) for con-
trols for GM; for WM it was 0.0334 (0.0131) for patients and 0.0042
(0.0045) for controls. The corresponding patient-control group differ-
ences are 0.0238 (0.0118) for GM and 0.0292 (0.0138) for WM. In
terms of average effect size over all signiﬁcant voxels, the yearly rate
of volume fraction change was −0.0310 (0.0115) for patients and
0.0015 (0.0009) for controls, for GM; for WM it was 0.0377 (0.0138)
for patients and 0.0001 (0.0045) for controls. The corresponding pa-
tient-control group differences are 0.0325 (0.0122) for GM and
0.0376 (0.0125) for WM.
There were no voxels for which the opposite contrast (rates of WM
or GM volume increase in patients signiﬁcantly greater than in control
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signiﬁcant.
4. Discussion
We have shown, in patients with various forms of human prion dis-
ease and varying individual rates of disease progression, that longitudi-
nal voxel-based morphometry can detect brain regions in which local
tissue volume reduction correlates signiﬁcantly with decline in func-
tional capacity over the same interval.We also quantiﬁed the equivalent
yearly rate of local tissue volume loss, and determined brain regions in
which this was greater than in controls. Combined, these ﬁndings sup-
port the validity of VBM–determined volume change as a clinically rel-
evant marker of prion disease progression and provide new evidence
regarding the neuroanatomical correlates of prion disease.
This is the ﬁrst study to investigate voxelwise longitudinal volume
change in prion disease across the whole brain. Our cohort of 24 pa-
tients is one of the largest with this rare condition studied longitudinal-
ly, with phenotypic heterogeneity representative of the range of clinical
phenotype seen at our national centre. The use of a 32-channel head coil
at 3T, is likely to offer improved sensitivity compared with earlier MRI
studies in prion disease. Our processing approach, with intra-subject
image alignment via high-dimensional warping, and inter-subject
DARTEL-based warping for longitudinal normalization for VBM, pro-
vides accurate normalization of themultiple individual scans and allows
voxelwise comparison of longitudinal structural brain changes with
modest spatial smoothing (6 mm).
The patient group deteriorated at varying rates,with progressive im-
pairment of cognition, speech, mobility and ability to care for them-
selves. This is typical of prion disease in general and these different
aspects of prion disease progression are reﬂected in changes in the
MRC Scale. Pathologically, this deterioration is due to the hallmark
prion disease histopathological changes of progressive accumulation
of prion protein aggregates with ensuing spongiosis, astrocytic gliosis
and nerve cell loss, common to all aetiological groups.
We hypothesized that these microscopic changes are reﬂected in
measureable WM and GM macroscopic changes. Structural MRI at
1.1 mm isotropic resolution with subsequent 6 mm spatial smoothing,
necessarily measures volume changes averaged over a large number
of neurons, axons and glial cells. Nevertheless we expect that local tis-
sue integrity, quantiﬁed in terms of fractional GM and WM differences
estimated by segmentation of T1-weighted images, will be sensitive to
these changes. Our ability to detect such changes with statistical signif-
icance depends not only on the degree of microscopic tissue disruption,
but also on the signal-to-noise-ratio of the measurement.
Prion disease patients displayed signiﬁcant longitudinal volume loss
correlating with decreased MRC Scale, partially overlapping with re-
gions where yearly rates of volume loss signiﬁcantly exceeded those
in controls in a number of areas: head of caudate, putamen, thalamus,
hippocampus, insular cortex, inferior frontal gyrus (pars opercularis),
splenium and genu of corpus callosum, pons, parts of the superior fron-
tal gyrus, middle temporal gyrus. Although the corpus callosum is non-
speciﬁc, many of these areas such as the basal ganglia and thalamus are
known to show changes on conventional MRI (T2-weighted, FLAIR, DW
images) or are functionally associatedwith speciﬁc aspects of prion dis-
ease clinical presentation (Tschampa et al., 2007). The putamen and
caudate nuclei receive input from diverse cortical areas, including pre-
frontal and limbic structures with non-motor output from the striatum
projecting via the mediodorsal and ventrolateral thalamic nuclei to the
dorsolateral prefrontal cortex, lateral orbitofrontal cortex and the ante-
rior cingulate and are key structures involved in memory circuits. The
mesial temporal lobe and frontal volume loss corresponds well to the
known frontal executive dysfunction andmemory loss in these patients.
Hippocampal involvement has been already observed cross-sectionally
in a VBM study of 6-OPRI inherited prion patients performed at 1.5T (De
Vita et al., 2013).The regionswhere only the correlation between tissue loss andMRC
Scale decline reached signiﬁcance included: parahippocampal gyrus,
precuneus, superior parietal lobule, occipital cortex and WM (superi-
or/middle occipital gyrus), parietal WM, vertical ﬁbers of arcuate fascic-
ulus, cortico-spinal tract ﬁbers at the level of the centrum semiovale and
the pons. Apraxia is an important feature in prion diseases, known to be
associated with parietal lobe dysfunction. Ataxia is known to be associ-
ated with pontine pathologies. The correlation between tissue loss and
MRC Scale decline appeared to highlight relatively few cortical struc-
tures. This may be due to the fact the MRC Scale is a composite rating
scale of overall patient function and cannot be directly linked to speciﬁc
cortical regions.
Signiﬁcant cortical thinning was shown in the precuneus, inferior
parietal cortex, supramarginal gyrus in a group of 18 6-OPRI patients
(Alner et al., 2012); VBM demonstrated volume loss in many cortical
and WM regions including the corpus callosum in 9 6-OPRI patients
(De Vita et al., 2013). VBMwas also used to reveal focal cerebellar atro-
phy in 11 sporadic CJD patients with cerebellar syndrome (Cohen et al.,
2009). Cerebellar and widespread supra-tentorial volume loss was also
reported in a single P102L gene carrier (Fox et al., 1997). Cortico spinal
tract WM involvement was detected by measuring diffusion changes
(Lee et al., 2012) (alongside internal capsule, external capsule, fornix,
and posterior thalamic radiation). Another study (Caverzasi et al.,
2014a) using FreeSurfer reported in sporadic CJD signiﬁcant cross-sec-
tional changes in diffusion properties in a number of regions, and
some cortical thickness reduction trends but could not demonstrate
any atrophy, cross-sectionally or longitudinally.
Our results are thus broadly consistentwith previous reports on var-
ious prion disease sub-types. However thesewere either cross-sectional
or focused on microscopic tissue water distribution changes (e.g. DTI),
whilst we demonstrated regional macroscopic volumetric changes
over time. While it is to be expected that complementary MRI metrics
detect change in consistent regions, their temporal relationship – if elu-
cidated in futuremultimodal longitudinal studies –may provide impor-
tant pathophysiological insights.
Correlation of local brain volume loss with an established rating
scale supports the biological and clinical validity of quantitative MRI
as a potential secondary outcome measure in treatment trials. This is
particularly relevant since potential therapies aiming to slow prion dis-
ease progression are in preclinical development (Freir et al., 2011).
While the MRC Scale provides a simple, accessible, yet useful clinical-
ly-oriented tool to monitor therapeutic efﬁcacy, quantitative imaging
may provide valuable complementary, objective and sensitive mea-
sures of progression.
4.1. Limitations of the study and future work
Though larger than similar prior studies, our sample size was still
limited, due to the rarity of the disease, and the difﬁculties some pa-
tients have with tolerating MRI, especially in late-stage disease. Indeed
the number of sporadic CJD patients that could undergo structural MRI
without sedation or general anaesthetic at more than one time-point
was extremely low: their fraction in our cohort was much lower than
their incidence in the wider prion patient population (approximately
85%). Similarly, the fraction of inherited prion disease patients was
higher in our cohort than the 10–15% fraction in the wider prion pa-
tients population; this reﬂects the higher relative prevalence and longer
clinical duration of this subtype.
Therefore, whilst we still included a range of patients with slow, in-
termediate and rapid functional/neurological decline (Fig.1), caution is
required in generalizing our ﬁndings, which may be speciﬁc to this
group, to wider or more-speciﬁc sub-populations. Future multi-centre
studies may provide access to a larger range of patients, making more
etiologically homogeneous subgroup analyses possible.
Furthermore,whilst our cohort is heterogenous, the underlying neu-
ropathologicalmechanisms are common across prion sub-types; having
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we were thus able to detect signiﬁcant speciﬁc regional involvement,
likely to reﬂect common neuroanatomic correlates of clinical decline
across all prion sub-types included. Studying an heterogenous cohort
allowed us to increase numbers and ensuing statistical power.
Voxel-wise statistical analyses must address the problem of multi-
ple-comparison. To asses statistical signiﬁcance we used a 5% voxelwise
false discovery rate threshold, similar to studies using comparable ap-
proaches (Rohrer et al., 2013). This threshold limits the number of
false negatives but is prone to producing false positives. Nevertheless,
the absence of signiﬁcant regions on opposite contrasts and the overall
anatomical consistency of the two analyses (and the overall agreement
with present knowledge of prion disease neurodegeneration patterns)
provide additional conﬁdence in the validity of the results.
One of the main criticisms of VBM focused on its reliance on imper-
fect image registration (Bookstein, 2001). To address this, the low-di-
mensional basis-function approach used in early work has here been
replaced with a high-dimensional diffeomorphic approach (Ashburner,
2007) that has been shown to perform very well (Klein et al., 2009).
Methods other than longitudinal VBM exist to study atrophy pro-
gression, such as Tensor Based Morphometry (Hua et al., 2011) or
methods based on FreeSurfer (Dale et al., 1999; Fischl et al., 1999;
Reuter et al., 2012) (see for instance (Caverzasi et al., 2014a, 2014b;
Landin-Romero et al., 2016; Holland et al., 2012)). Longitudinal TBM
and VBM are very closely related, since both rely on the Jacobian deter-
minants from spatial transformations to characterise volume change.
However VBM combines the registration-based volume-change infor-
mation with tissue probability information. This extra information can
increase sensitivity in areas of boundary between atrophic grey matter
and expanding CSF where naive smoothing of TBMmaps can cause par-
tial cancellation. Procedures based on FreeSurfer's parcellation and seg-
mentation have not yet been carefully compared to longitudinal VBM in
the literature, and the relative advantages of each methodology might
vary by region. One of the beneﬁts of longitudinal VBM is that it is
fully automated whilst FreeSurfer might require time-consuming man-
ual interaction for optimal results in challenging regions [e.g. https://
surfer.nmr.mgh.harvard.edu/fswiki/Edits]). Further work will explore
alternative atrophy assessment techniques.
A few previous studies have shown a relationship between involve-
ment of the striatumand shorter disease course (Gao et al., 2015; Kim et
al., 2011; Yi et al., 2008). A recent longitudinal study reported at follow-
up an increased DWI signal mainly in the striatum (Eisenmenger et al.,
2016). As the present study demonstrates signiﬁcant atrophy in the
striatum, it would be extremely interesting to analyse the relationship
between DWI and atrophy changes, across the whole brain and particu-
larly in the striatum. This will be addressed in future work.
5. Conclusions
We have presented the ﬁrst 3T MRI longitudinal voxel-based analy-
sis of brain structural change in prion disease in a cohort of patientswith
various forms of the disease (the majority having inherited prion dis-
ease), at an early stage of the disease course. We identiﬁed progressive
volume loss in basal ganglia, cortical andWM regions that relate to pre-
vious cross-sectional imaging ﬁndings and to functional deﬁcits associ-
ated with disease progression. With the current data, it is not yet
possible to establish whether MRI-determined brain volume loss pre-
cedes clinical change quantiﬁed according to functional scales such as
the MRC Scale. Nevertheless, localisation of regions of progressive
brain atrophy correlating most strongly with clinical decline may help
to determine more effective imaging endpoints for future clinical trials.
In this respect it will be important to compare the usefulness of brain at-
rophy vs. other imaging measures, including diffusion weighted imag-
ing metrics.
Supplementary data to this article can be found online at http://dx.
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